Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications
Factors Impacting Overall Survival Post-Relapse in High-Risk Neuroblastoma: Children's Oncology Group Outcomes From 2000 to 2019.
Journal: Pediatric blood & cancer
Published: March 16, 2026
A pilot study of chemoimmunotherapy in the postconsolidation setting for high-risk neuroblastoma (ANBL19P1): A report from the Children's Oncology Group.
Journal: Cancer
Published: August 27, 2025
Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 23, 2025
Venetoclax in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results of a Phase 1 Study.
Journal: Pediatric blood & cancer
Published: April 11, 2025
Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum.
Journal: Pediatric blood & cancer
Published: February 26, 2025
Protocol for 3D bioprinting of a 3D in vitro model of neuroblastoma.
Journal: STAR protocols
Published: January 03, 2025
Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Myeloid Leukaemia.
Journal: Pediatric blood & cancer
Published: November 14, 2024
Trends in analgesia-sedation of pediatric patients receiving I-131 MIBG in the pediatric intensive care unit: A report from the Pediatric Health Information System database.
Journal: Pediatric blood & cancer
Published: May 23, 2024
Current and Emerging Biomarkers: Impact on Risk Stratification for Neuroblastoma.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 10, 2024
The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1.
Journal: Oncoimmunology
Published: August 09, 2023
Children's Oncology Group's 2023 blueprint for research: Neuroblastoma.
Journal: Pediatric blood & cancer
Published: June 30, 2023
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
Journal: Nature communications
Published: January 08, 2023
Last Updated: 09/26/2026